X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TORRENT PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA TORRENT PHARMA AUROBINDO PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 14.3 60.3 23.7% View Chart
P/BV x 2.9 5.7 50.7% View Chart
Dividend Yield % 0.4 0.9 48.2%  

Financials

 AUROBINDO PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
TORRENT PHARMA
Mar-18
AUROBINDO PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8091,550 52.2%   
Low Rs5041,144 44.1%   
Sales per share (Unadj.) Rs281.1354.7 79.2%  
Earnings per share (Unadj.) Rs41.440.1 103.2%  
Cash flow per share (Unadj.) Rs50.964.2 79.2%  
Dividends per share (Unadj.) Rs2.5014.00 17.9%  
Dividend yield (eoy) %0.41.0 36.6%  
Book value per share (Unadj.) Rs199.4273.1 73.0%  
Shares outstanding (eoy) m585.88169.22 346.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.8 61.5%   
Avg P/E ratio x15.933.6 47.2%  
P/CF ratio (eoy) x12.921.0 61.5%  
Price / Book Value ratio x3.34.9 66.8%  
Dividend payout %6.034.9 17.3%   
Avg Mkt Cap Rs m384,630227,897 168.8%   
No. of employees `00017.314.7 117.9%   
Total wages/salary Rs m21,30811,353 187.7%   
Avg. sales/employee Rs Th9,500.74,083.0 232.7%   
Avg. wages/employee Rs Th1,229.4772.3 159.2%   
Avg. net profit/employee Rs Th1,397.9461.3 303.0%   
INCOME DATA
Net Sales Rs m164,66660,021 274.3%  
Other income Rs m1,0202,988 34.1%   
Total revenues Rs m165,68663,009 263.0%   
Gross profit Rs m37,71813,493 279.5%  
Depreciation Rs m5,5804,086 136.6%   
Interest Rs m7773,085 25.2%   
Profit before tax Rs m32,3809,310 347.8%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1832,529 323.6%   
Profit after tax Rs m24,2296,781 357.3%  
Gross profit margin %22.922.5 101.9%  
Effective tax rate %25.327.2 93.0%   
Net profit margin %14.711.3 130.2%  
BALANCE SHEET DATA
Current assets Rs m121,87852,623 231.6%   
Current liabilities Rs m86,80652,022 166.9%   
Net working cap to sales %21.31.0 2,125.3%  
Current ratio x1.41.0 138.8%  
Inventory Days Days130120 108.6%  
Debtors Days Days6876 89.7%  
Net fixed assets Rs m81,03785,016 95.3%   
Share capital Rs m586846 69.2%   
"Free" reserves Rs m116,21845,376 256.1%   
Net worth Rs m116,80446,222 252.7%   
Long term debt Rs m4,51241,115 11.0%   
Total assets Rs m211,052142,432 148.2%  
Interest coverage x42.74.0 1,061.8%   
Debt to equity ratio x00.9 4.3%  
Sales to assets ratio x0.80.4 185.1%   
Return on assets %11.86.9 171.0%  
Return on equity %20.714.7 141.4%  
Return on capital %27.414.2 192.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72714,580 553.7%   
Fx outflow Rs m34,7003,600 963.9%   
Net fx Rs m46,02710,980 419.2%   
CASH FLOW
From Operations Rs m19,5488,942 218.6%  
From Investments Rs m-19,570-47,070 41.6%  
From Financial Activity Rs m8,64234,174 25.3%  
Net Cashflow Rs m8,922-3,655 -244.1%  

Share Holding

Indian Promoters % 54.1 71.5 75.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 7.0 113.2%  
FIIs % 27.7 12.6 219.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.8 115.9%  
Shareholders   69,601 26,511 262.5%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  VENUS REMEDIES  PIRAMAL ENTERPRISES  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 160 Points Higher; IT and Healthcare Stocks Witness Buying(Closing)

Indian share markets traded on a positive note most of the day and ended higher. Gains were largely seen in the IT sector and healthcare sector, while capital goods stocks witnessed selling pressure.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

This Smallcap Stock could be the next Page Industries(Profit Hunter)

Jul 2, 2019

The smallcap rebound is taking longer to play out...and that's good news as it gives you more of action time and opportunities to invest in.

The Indian Rating Agency Cleanup Has Begun and this Cheap Stock Could be the Best Bet(The 5 Minute Wrapup)

Jul 2, 2019

The last time this big rating agency was as cheap and out-of-favour as it is today, the stock had corrected by 40% in six months.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 15, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS